IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety and tolerability of utilizing
the insulin-like growth factor-1-methotrexate conjugate, 765IGF-MTX for the treatment of
advanced, previously treated myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia
(CMML) and oligoblastic acute myelogenous leukemia (oligoblastic AML or O-AML), including
determining the maximum tolerated dose (MTD).